Advertisement
Canada markets closed

  • S&P/TSX

    21,554.86
    -26.44 (-0.12%)
     

  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     

  • DOW

    39,150.33
    +15.53 (+0.04%)
     

  • CAD/USD

    0.7304
    -0.0003 (-0.04%)
     

  • CRUDE OIL

    80.59
    -0.14 (-0.17%)
     

  • Bitcoin CAD

    87,761.37
    -236.16 (-0.27%)
     

  • CMC Crypto 200

    1,321.70
    -38.63 (-2.84%)
     

  • GOLD FUTURES

    2,334.70
    +3.50 (+0.15%)
     

  • RUSSELL 2000

    2,022.03
    +4.64 (+0.23%)
     

  • 10-Yr Bond

    4.2570
    +0.0030 (+0.07%)
     

  • NASDAQ

    17,689.36
    -32.24 (-0.18%)
     

  • VOLATILITY

    13.20
    -0.08 (-0.60%)
     

  • FTSE

    8,237.72
    -34.74 (-0.42%)
     

  • NIKKEI 225

    38,596.47
    -36.53 (-0.09%)
     

  • CAD/EUR

    0.6830
    +0.0009 (+0.13%)
     

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series

AIM ImmunoTech Inc.
·1 min read
AIM ImmunoTech Inc.
AIM ImmunoTech Inc.

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, June 5th at 12:00 PM ET

OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series on Wednesday, June 5, 2024 at 12:00 PM ET.

As part of the event, Mr. Equels will provide a corporate overview and business outlook. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the event. Mr. Equels will answer as many questions as possible in the time allowed.

ADVERTISEMENT

A live video webcast of the presentation will be available on the Events page of the Company’s website (aimimmuno.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com